RxDoctor Payments Data

Lynnette Parker

Family · Battle Creek, MINPI 1699495952

Payments from drug & device makers

$2,205in general payments, 2019–2025

Across 111 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$372
  • Pfizer$267
  • AstraZeneca$249
  • AbbVie$232
  • Otsuka America Pharmaceutical, Inc.$151
  • Lilly USA, LLC$145
  • plus $789 from 16 others

What the payments were for

  • Food & beverage$2,205100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,205 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$13,495
Medicare patients
122
Services billed
189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$23,397
EliquisApixaban21$16,536
TrulicityDulaglutide12$13,246
JanuviaSitagliptin Phosphate11$5,986
Duloxetine Hcl38$2,688
Albuterol Sulfate HfaAlbuterol Sulfate54$1,812
Atorvastatin Calcium99$1,561
Gabapentin64$1,237
Omeprazole79$928
Ventolin HfaAlbuterol Sulfate12$887
Celecoxib17$857
Levothyroxine Sodium73$851
Tamsulosin Hcl22$822
Rosuvastatin Calcium44$813
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen44$740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$372$23,39720 claims
PfizerEliquis$267$16,53621 claims
Lilly USA, LLCTrulicity$145$13,24612 claims
MerckJanuvia$138$5,98611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.

Other family in Battle Creek

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →